NCT07522606 is a clinical trial of BIA 28-6156 in Parkinson Disease, sponsored by Bial R&D Investments, S.A..

Who is sponsoring NCT07522606?

NCT07522606 is sponsored by Bial R&D Investments, S.A..

What drugs are being tested in NCT07522606?

Interventions in NCT07522606: BIA 28-6156.

What condition does NCT07522606 study?

NCT07522606 studies Parkinson Disease.

Is NCT07522606 still recruiting?

NCT07522606 is currently available. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT07522606

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study

AVAILABLE Last updated 13 April 2026

What this trial tests

trial testing BIA 28-6156 in Parkinson Disease. Available.

Quick facts

Lead sponsor	Bial R&D Investments, S.A.
Status	AVAILABLE
Study type	EXPANDED_ACCESS
Sites	36 locations across Italy, United Kingdom, Portugal, United States, Spain

Drugs / interventions tested

BIA 28-6156

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Bial R&D Investments, S.A. — full company profile →

Who can join

Eligibility, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Bial R&D Investments, S.A. trials

Trials by the same sponsor.

NCT05819359 — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD · Phase 2 · active not recruiting
NCT05220072 — Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07522606 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bial R&D Investments, S.A.
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07522606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing